Literature DB >> 18680763

Suppression of dendritic cell differentiation through cytokines released by Primary Effusion Lymphoma cells.

Mara Cirone1, Giuseppe Lucania, Silvia Aleandri, Giuliana Borgia, Pankaj Trivedi, Laura Cuomo, Luigi Frati, Alberto Faggioni.   

Abstract

Functional impairment of dendritic cells (DC) appears to be one of the mechanisms responsible for tumor escape from the control of the immune system. DC isolated from tumor-bearing animals and cancer patients with solid or with hematological malignancies have phenotypic and functional abnormalities. In addition, supernatants from in vitro cultured tumor cells have been shown to interfere with DC differentiation from CD34+ and monocyte precursors. Primary effusion lymphoma (PEL) is a Human Herpesvirus-8 (HHV-8)-associated tumor, which releases several cytokines such as IL-6, IL-10 and VEGF and its growth seems to be dependent on them in vitro or in vivo. In the present study, we found that these cytokines released by PELs have also an important role in interfering with the in vitro differentiation of immature DC (iDC) from CD14+ monocytes. The iDC obtained in the presence of PEL supernatants showed reduction of FITC-dextran uptake, reduction of MLR allostimulatory activity and altered expression of surface molecules, suggesting that cytokines released by PEL adversely affect DC differentiation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18680763     DOI: 10.1016/j.imlet.2008.06.011

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  24 in total

Review 1.  Viral miRNAs: tools for immune evasion.

Authors:  Isaac W Boss; Rolf Renne
Journal:  Curr Opin Microbiol       Date:  2010-06-25       Impact factor: 7.934

Review 2.  Viral miRNAs and immune evasion.

Authors:  Isaac W Boss; Rolf Renne
Journal:  Biochim Biophys Acta       Date:  2011-07-05

3.  KSHV activation of VEGF secretion and invasion for endothelial cells is mediated through viral upregulation of emmprin-induced signal transduction.

Authors:  Lu Dai; Momka Bratoeva; Bryan P Toole; Zhiqiang Qin; Chris Parsons
Journal:  Int J Cancer       Date:  2011-10-24       Impact factor: 7.396

4.  Low expression of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in non-Hodgkin lymphoma and a significant correlation with β2-microglobulin.

Authors:  Dongbing Ding; Wenbin Chen; Changfu Zhang; Zhe Chen; Yanmei Jiang; Ziyi Yang; Xudong Jiang; Yunfei Zuo; Shuangyi Ren
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

5.  Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes.

Authors:  Zhiqiang Qin; Patricia Kearney; Karlie Plaisance; Chris H Parsons
Journal:  J Leukoc Biol       Date:  2010-01       Impact factor: 4.962

6.  Methionine enkephalin (MENK) improved the functions of bone marrow-derived dendritic cells (BMDCs) loaded with antigen.

Authors:  Weiwei Li; Jingjuan Meng; Xuan Li; Hui Hua; Meng Yiming; Qiushi Wang; Enhua Wang; Fengping Shan
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

7.  Cytokine production by human herpesvirus 8-infected dendritic cells.

Authors:  Heather R Hensler; Giovanna Rappocciolo; Charles R Rinaldo; Frank J Jenkins
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

Review 8.  Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.

Authors:  Chuang Sun; Gianpietro Dotti; Barbara Savoldo
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

9.  An RNA element in human interleukin 6 confers escape from degradation by the gammaherpesvirus SOX protein.

Authors:  Stephanie Hutin; Yeon Lee; Britt A Glaunsinger
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

Review 10.  Immune escape of γ-herpesviruses from adaptive immunity.

Authors:  Zhuting Hu; Edward J Usherwood
Journal:  Rev Med Virol       Date:  2014-04-15       Impact factor: 6.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.